Modus Therapeutics Holding
1.25
SEK
-2.34 %
Less than 1K followers
MODTX
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
-2.34%
-6.02%
-30.75%
-33.33%
-23.55%
+9.65%
-67.49%
-
-76.19%
Modus Therapeutics operates in the biotechnology industry. The product portfolio is broad and includes, for example, sevuparin. The company's focus is to develop sevuparin for patients with sepsis / septic shock, a serious and often fatal condition. In addition to the main business, service and associated ancillary services are also offered. The activities with associated research are conducted in Sweden.
Read moreMarket cap
44.92M SEK
Turnover
67.78K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
14/5
2025
Interim report Q1'25
20/5
2025
General meeting '25
27/8
2025
Interim report Q2'25
All
Press releases
3rd party
ShowingAll content types
Carnegie Access: Modus Therapeutics Holding: Highlights from Carnegie’s Healthcare Conference
Modus Therapeutics meddelar fullgjord patientrekrytering i Fas I-studien SEVUSMART vid svår malaria
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools